➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Merck
McKinsey
Medtronic

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 6,676,977

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,676,977
Title: Pharmaceutical compositions and methods for reducing the appearance of cellulite
Abstract:Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.
Inventor(s): Murad; Howard (Marina del Rey, CA)
Assignee:
Application Number:10/051,189
Patent Claims:see list of patent claims

Details for Patent 6,676,977

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial 2019-08-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Mallinckrodt
McKesson
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.